Genmab A/S (GMAB) PT Raised to $32 at TD Cowen

TD Cowen analyst Yaron Werber raised the price target on Genmab A/S (NASDAQ: GMAB) to $32.00 (from $24.00) while maintaining a Hold rating.

The analyst comments "GMAB to acquire MRUS for $97/share (~$8B cash), gaining petosemtamab (EGFRxLGR5; in Ph3 for HNSCC with data in 2026). Peto should support multi-billion potential in HNSCC, with CRC as upside; deal should be accretive by 2029. This accelerates GMAB's shift from royalty to wholly owned model with long-term growth. Deal should close by early Q1:26, enabling multiple drug launches by 2027."

You May Also Be Interested In

• Guggenheim Downgrades Alumis Inc (ALMS) to Neutral
• DelphX closes C$52,500 private placement, updates on CRS platform
• Lotus Creek output tops 5,500 boe/d, exceeding quarterly guidance